Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
2.

Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO).

Chaigneau L, Patrikidou A, Ray-Coquard I, Valentin T, Linassier C, Bay JO, Moureau Zabotto L, Bompas E, Piperno-Neumann S, Penel N, Alcindor T, Laigre M, Guillemet C, Salas S, Hugli A, Domont J, Sunyach MP, Lecesne A, Blay JY, Nerich V, Isambert N.

Oncologist. 2018 Aug;23(8):948-955. doi: 10.1634/theoncologist.2017-0136. Epub 2018 Jun 22.

PMID:
29934413
3.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

PMID:
29860937
4.

Age and factors associated with access and time to post-operative adjuvant chemotherapy in colon cancer: a French epidemiological study.

Capsec J, Lefebvre C, Chupé F, Heitzmann P, Raveneau C, Dardaine-Giraud V, Sauger C, Lagasse JP, Kraft K, Linassier C, Dorval E.

J Gastrointest Oncol. 2017 Oct;8(5):842-849. doi: 10.21037/jgo.2017.06.13.

5.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

Loriot Y, Pagliaro L, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Laplanche A, Le Teuff G, Culine S, Fizazi K.

Eur J Cancer. 2017 Dec;87:140-146. doi: 10.1016/j.ejca.2017.09.029. Epub 2017 Nov 14.

PMID:
29149760
6.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
7.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Review.

8.

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).

Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, Isambert N, Thariat J, Linassier C, Bertucci F, Bay JO, Bellesoeur A, Penel N, Le Guellec S, Filleron T, Chevreau C.

Eur J Cancer. 2016 Mar;56:77-84. doi: 10.1016/j.ejca.2015.12.015. Epub 2016 Jan 26.

PMID:
26824706
9.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
10.

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.

Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H.

Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5.

PMID:
25943350
11.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves Blay J; French Sarcoma Group.

Eur J Cancer. 2015 Apr;51(6):742-50. doi: 10.1016/j.ejca.2015.01.006. Epub 2015 Feb 23.

PMID:
25727882
12.

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S.

Ann Oncol. 2015 Feb;26(2):378-85. doi: 10.1093/annonc/mdu552. Epub 2014 Dec 1.

PMID:
25467013
13.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-50. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

14.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S.

Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30.

PMID:
25277272
15.

Computer-assisted management of unconsumed drugs as a cost-containment strategy in oncology.

Respaud R, Tournamille JF, Saintenoy G, Linassier C, Elfakir C, Viaud-Massuard MC, Antier D.

Int J Clin Pharm. 2014 Oct;36(5):892-5. doi: 10.1007/s11096-014-9974-1. Epub 2014 Jul 13.

PMID:
25022715
16.

Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study.

Cassier PA, Kantor G, Bonvalot S, Lavergne E, Stoeckle E, Le Péchoux C, Meeus P, Sunyach MP, Vaz G, Coindre JM, Linassier C, Labib A, Delcambre C, Bay JO, Leyvraz S, Dubergé T, Lagrange JL, Duret A, Blay JY.

Ann Oncol. 2014 Sep;25(9):1854-60. doi: 10.1093/annonc/mdu202. Epub 2014 Jun 8.

PMID:
24914041
17.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K.

Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11.

PMID:
24424105
18.

Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.

Joly F, Delva R, Mourey L, Sevin E, Bompas E, Vedrine L, Ravaud A, Eymard JC, Tubiana-Mathieu N, Linassier C, Houede N, Guillot A, Ringensen F, Cojocarasu O, Valenza B, Leconte A, Lheureux S, Clarisse B, Oudard S.

BJU Int. 2015 Jan;115(1):65-73. doi: 10.1111/bju.12552.

19.

Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients.

Dumont SN, Araujo DM, Munsell MF, Salganick JA, Dumont AG, Raymond KA, Linassier C, Patel S, Benjamin RS, Trent JC.

Cancer Med. 2013 Aug;2(4):553-63. doi: 10.1002/cam4.92. Epub 2013 Jul 15.

20.

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.

Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548.

21.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M.

Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8.

PMID:
23306100
22.

The role of imaging in staging and monitoring testicular cancer.

Brunereau L, Bruyère F, Linassier C, Baulieu JL.

Diagn Interv Imaging. 2012 Apr;93(4):310-8. doi: 10.1016/j.diii.2012.01.014. Epub 2012 Mar 30. Review.

23.

Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.

Linassier C, Carmier D, Combe P, D'Arcier BF, Bruyere F, Narciso B.

Anticancer Res. 2012 Feb;32(2):697-700.

PMID:
22287765
24.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S.

Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24.

PMID:
22119204
25.

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, Maroto JP, Powles T, De Santis M.

Med Oncol. 2012 Sep;29(3):1896-907. doi: 10.1007/s12032-011-0016-8. Epub 2011 Jul 7. Review.

PMID:
21735145
26.

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.

Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E.

Cancer Immunol Immunother. 2011 Feb;60(2):261-71. doi: 10.1007/s00262-010-0935-9. Epub 2010 Nov 11.

PMID:
21069322
27.

VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma.

Bruyère F, Hovens CM, Marson MN, d'Arcier BF, Costello AJ, Watier H, Linassier C, Ohresser M.

J Urol. 2010 Oct;184(4):1273-8. doi: 10.1016/j.juro.2010.06.009. Epub 2010 Aug 17.

PMID:
20723915
28.

Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.

Lesimple T, Riffaud L, Frappaz D, Ben Hassel M, Gédouin D, Bay JO, Linassier C, Hamlat A, Piot G, Fabbro M, Saïkali S, Carsin B, Guégan Y.

J Neurooncol. 2009 Jun;93(2):253-60. doi: 10.1007/s11060-008-9774-3. Epub 2009 Jan 13.

PMID:
19139825
29.

Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.

Munnier E, Cohen-Jonathan S, Linassier C, Douziech-Eyrolles L, Marchais H, Soucé M, Hervé K, Dubois P, Chourpa I.

Int J Pharm. 2008 Nov 3;363(1-2):170-6. doi: 10.1016/j.ijpharm.2008.07.006. Epub 2008 Jul 16.

PMID:
18687392
30.

Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles.

Douziech-Eyrolles L, Marchais H, Hervé K, Munnier E, Soucé M, Linassier C, Dubois P, Chourpa I.

Int J Nanomedicine. 2007;2(4):541-50. Review.

31.

Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study.

Marino P, Roché H, Biron P, Janvier M, Spaeth D, Fabbro M, Linassier C, Delozier T, Martin AL, Santin G, Moatti JP; PEGASE Group.

Value Health. 2008 Jul-Aug;11(4):709-18. doi: 10.1111/j.1524-4733.2007.00306.x. Epub 2008 Jan 8.

32.

On the interaction of doxorubicin with oleate ions: fluorescence spectroscopy and liquid-liquid extraction study.

Munnier E, Tewes F, Cohen-Jonathan S, Linassier C, Douziech-Eyrolles L, Marchais H, Soucé M, Hervé K, Dubois P, Chourpa I.

Chem Pharm Bull (Tokyo). 2007 Jul;55(7):1006-10.

33.

Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles.

Okassa LN, Marchais H, Douziech-Eyrolles L, Hervé K, Cohen-Jonathan S, Munnier E, Soucé M, Linassier C, Dubois P, Chourpa I.

Eur J Pharm Biopharm. 2007 Aug;67(1):31-8. Epub 2007 Jan 12.

PMID:
17289360
34.

Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.

Bay JO, Linassier C, Biron P, Durando X, Verrelle P, Kwiatkowski F, Rosti G, Demirer T; EMBT solid tumors working party.

Int J Cancer. 2007 Apr 15;120(8):1782-6. Erratum in: Int J Cancer. 2007 Nov 15;121(10):2355. Jacques-Olivier, Bay [corrected to Bay, Jacques-Olivier]; Claude, Linassier [corrected to Linassier, Claude]; Pierre, Biron [corrected to Biron, Pierre]; Xavier, Durando [corrected to Durando, Xavier]; Pierre, Verrelle [corrected to Verrelle, Pierre]; Fabr.

35.

Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.

Le Deley MC, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C.

J Clin Oncol. 2007 Jan 20;25(3):292-300. Epub 2006 Dec 11.

PMID:
17159192
36.

High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T.

Bone Marrow Transplant. 2006 Sep;38(6):417-20.

PMID:
16951691
37.

Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study.

Gonçalves A, Delva R, Fabbro M, Gladieff L, Lotz JP, Ferrero JM, Linassier C, Cottu PH, Viens P, Extra JM.

Bone Marrow Transplant. 2006 Apr;37(7):651-9.

PMID:
16501596
38.

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.

J Clin Oncol. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

PMID:
15738542
39.

[Agranular CD4+ CD56+ CD123+ hematodermic neoplasm (blastic NK-cell lymphoma) revealed by cutaneous localization: 2 cases].

Machet L, De Muret A, Wiezberka E, Bernez A, Abdallah-Lotf M, Linassier C, Petrella T.

Ann Dermatol Venereol. 2004 Nov;131(11):969-73. French.

PMID:
15602384
40.

[Standards, Options and Recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)].

Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, Chatel M, Figarella-Branger D, Guegan Y, Guyotat J, Khé HX, Jouanneau E, Keime-Guibert F, Laforêt C, Linassier C, Loiseau H, Menel P, Rousmans S, Sanson M, Sunyach MP.

Bull Cancer. 2003 Oct;90(10):873-86. Review. French. Erratum in: Bull Cancer. 2003 Dec;90(12):1096.

41.

Summary version of the Standards, Options and Recommendations for the management of adult patients with intracranial glioma (2002).

Frappaz D, Chinot O, Bataillard A, Ben Hassel M, Capelle L, Chanalet S, Chatel M, Figarella-Branger D, Guegan Y, Guyotat J, Hoang-Xuan K, Jouanneau E, Keime-Guibert F, Laforêt C, Linassier C, Loiseau H, Maire JP, Menei P, Rousmans S, Sanson M, Sunyach MP; FNCLCC; Neuro-oncology Group of the Fédération Nationale des Centres de Lutte Contre le Cancer; Association of French-speaking Neuro-oncologists.

Br J Cancer. 2003 Aug;89 Suppl 1:S73-83. No abstract available.

42.

Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow.

Benboubker L, Cartron G, Roingeard F, Delain M, Degenne M, Linassier C, Hérault O, Truglio D, Bout M, Petit A, Brémond JL, Desbois I, Colombat P, Binet C, Domenech J.

Exp Hematol. 2003 Jan;31(1):89-97.

PMID:
12543111
43.

Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group.

Linassier C, Desablens B, Lefrancq T, Le Prise PY, Harousseau JL, Jacob C, Gandhour C, Haillot O, Lucas V, Leloup R, Escoffre M, Colombat P, Tabuteau S; GOELAMS Study Group.

Clin Lymphoma. 2002 Dec;3(3):167-72.

PMID:
12521394
44.

A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma.

Bennouna J, Delva R, Gomez F, Lesimple T, Geoffrois L, Linassier C, Chevreau C, Douillard JY, Négrier S.

Oncology. 2003;64(1):25-7.

PMID:
12457028
45.

Phosphatidylinositol 3-kinases are involved in the all-trans retinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells.

Lewandowski D, Linassier C, Iochmann S, Degenne M, Domenech J, Colombat P, Binet C, Hérault O.

Br J Haematol. 2002 Aug;118(2):535-44.

PMID:
12139742
46.

[Malt lymphoma of the thyroid and Graves'disease].

Djrolo F, Gervaise N, Combe H, Linassier C, Lhuintre Y, Lecomte P.

Ann Endocrinol (Paris). 2001 Nov;62(5):442-5. French.

PMID:
11852351
47.

[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].

Linassier C, Destrieux C, Benboubker L, Alcaraz L, Bergemer-Fouquet AM, Jan M, Calais G, Colombat P.

Bull Cancer. 2001 Sep;88(9):871-6. Review. French.

48.

Multiple myeloma in elderly patients: presenting features and outcome.

Rodon P, Linassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M, Luthier F, Dugay J, Lucas V, Colombat P.

Eur J Haematol. 2001 Jan;66(1):11-7. Review.

PMID:
11168502
49.

A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.

Benboubker L, Valat C, Linassier C, Cartron G, Delain M, Bout M, Fetissof F, Lefranq T, Lamagnere JP, Colombat P.

Ann Oncol. 2000 Nov;11(11):1485-91.

PMID:
11142490
50.

Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.

Linassier C, Barin C, Calais G, Letortorec S, Brémond JL, Delain M, Petit A, Georget MT, Cartron G, Raban N, Benboubker L, Leloup R, Binet C, Lamagnère JP, Colombat P.

Ann Oncol. 2000 Oct;11(10):1289-94.

PMID:
11106118

Supplemental Content

Loading ...
Support Center